Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(arsenic trioxide)
3,907 results
  • [Russian multicenter clinical trials in acute leukemias]. [Journal Article]
    Ter Arkh. 2019 Jul 15; 91(7):4-13.Parovichnikova EN, Savchenko VG
  • The paper describes the results of 15 consecutive Russian clinical trials in the treatment of different types of acute leukemias, conducted by Russian cooperative group within the last 27-years and included more than 25 hundred patients. It was shown that the 5-years overall survival in AML younger than 60 years patients improved from 20 to 33%, in ALL - from 38 to 65%, in APL - from 0 to 95%. Th…
  • Extramedullary disease in acute promyelocytic leukaemia: A rare presentation. [Case Reports]
    SAGE Open Med Case Rep. 2020; 8:2050313X20926076.Kasinathan G, Sathar J
  • Acute promyelocytic leukaemia consists of 7%-8% of cases of acute myeloid leukaemia. Extramedullary manifestations are rare and show distinct biological features. We describe a 22-year-old female of Malay ethnicity who presented with fever and a left axillary swelling for a week. The peripheral blood smear showed abnormal promyelocytes with faggot cells. PML-RAR-alpha t(15;17) (q22; q12) was dete…
  • Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. [Journal Article]
    Leuk Lymphoma. 2020 Jun 14 [Online ahead of print]Liang C, Peng CJ, … Luo XQ
  • The prognosis of patients with acute myeloid leukemia (AML) caused by the FLT3-ITD mutation is poor. Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) can down-regulate FLT3-ITD level and selectively kill leukemia cells carrying the FLT3-ITD mutation. However, the mechanisms of action of these two compounds are unknown. Here, we found that ATO could bind FLT3-ITD at Lys91 and Asp225, wher…
  • Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia. [Review]
    Clin Transplant. 2020 Jun 11 [Online ahead of print]Hashmi H, Nishihori T
  • The use of all trans-retinoic acid and arsenic trioxide combination as the induction regimen for acute promyelocytic leukemia (APL) has revolutionized the management and outcomes of this disease. Modern risk adapted frontline therapy has provided excellent therapeutic results. However, significant numbers of APL patients relapse after frontline therapy, and the optimal management strategy for rel…
  • When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. [Review]
    Chemotherapy. 2020 Jun 10; 64(5-6):1-10.Gurnari C, De Bellis E, … Voso MT
  • Arsenic has been known for centuries for its double-edged potential: a poison and at the same time a therapeutic agent. The name "arsenikon," meaning "potent," speaks itself for the pharmaceutical properties of this compound, questioned and analyzed for at least 2000 years. In the last decades, acute promyelocytic leukemia (APL) has evolved from a highly fatal to a curable disease, due to the use…
  • Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review. [Review]
    Int J Hematol Oncol Stem Cell Res. 2020 Apr 01; 14(2):130-139.Mohammadi Kanesbi M, Jarahi L, Keramati MR
  • Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). APL is famed with some special blood coagulation disorders such as disseminated intravascular coagulation (DIC). The therapeutic methods of APL contain All Trans Retinoic Acid (ATRA), arsenic trioxide (ATO) or/and chemotherapy. Many studies have been done on APL blood disorders and its treatment. These studies have s…
  • iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas. [Journal Article]
    Biochem Biophys Res Commun. 2020 Jun 18; 527(1):117-123.Shi X, Ma R, … Piao JG
  • A poly(amidoamine) dendrimer (PAMAM, G5) based drug delivery system was developed for the treatment of glioma. PAMAM was modified with polyethylene glycol (PEG) to improve its in vivo stability and reduce immunogenicity. Further, the internalized RGD (iRGD) recognition ligand of the integrin αvβ3 receptor and the blood-brain barrier (BBB)-targeting group TGN were introduced. Arsenic trioxide (ATO…
  • Biotransformation of arsenic and toxicological implication of arsenic metabolites. [Review]
    Arch Toxicol. 2020 May 20 [Online ahead of print]Hirano S
  • Arsenic is a well-known environmental carcinogen and chronic exposure to arsenic through drinking water has been reported to cause skin, bladder and lung cancers, with arsenic metabolites being implicated in the pathogenesis. In contrast, arsenic trioxide (As2O3) is an effective therapeutic agent for the treatment of acute promyelocytic leukemia, in which the binding of arsenite (iAsIII) to promy…
  • Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. [Journal Article]
    Sci China Life Sci. 2020 May 06 [Online ahead of print]Liu X, Su Y, … Zhang X
  • This study aimed to explore macrophage polarization in acute graft-versus-host disease after hematopoietic stem cell transplantation, and investigated if arsenic trioxide (ATO) could correct this imbalance. In the colon of GVHD mice, we found that the number of F4/80+iNOS+ cells as well as the expression intensity of TNF-α and IL-1β was greater in the GVHD group than in the BM group, whereas the …
  • Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review. [Review]
    Int J Pharm. 2020 Jun 15; 583:119385.Fei W, Li C, … Zheng C
  • Arsenic trioxide (As2O3), a front-line therapeutic agent against acute promyelocytic leukemia, has a broad spectrum against malignancies. Unfortunately, the clinical application of As2O3 in treating hematological cancers has not been transformed to solid tumors, for its dose-limited toxicity and undesirable pharmacokinetics. The ordinary As2O3 loaded nanodrugs (such as liposomes, polymer micelles…
New Search Next